Development of microRNA amplifier to regulate cell-mediated immune responses
| Project/Area Number |
26861144
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 脊髄損傷 / ベバシズマブ / 血管内皮細胞増殖因子 / 炎症性浮腫 / 反応性アストロサイト / 二次損傷 / regulatory T cell / マイクロRNA / CTLA4-Ig / VEGF |
|---|
| Outline of Final Research Achievements |
Bevacizumab, an anti-VEGF monoclonal antibody, has been proposed as treatment for gliomas and radiation necrosis in the neurological field. In our study using spinal cord injury (SCI) mice, bevacizumab has been shown to alleviate focal inflammation and edema due to suppressed vascular hyper-permeability in the acute phase of secondary injury, leading to improvement of neurological function. Our results indicate that bevacizumab may become a promising drug for alleviating SCI.
|
Report
(3 results)
Research Products
(3 results)
